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Extracellular ATP drives systemic inflammation, tissue
damage and mortality
A Cauwels*,1,2, E Rogge1,2, B Vandendriessche1,2, S Shiva3 and P Brouckaert1,2
Systemic inflammatory response syndromes (SIRS) may be caused by both infectious and sterile insults, such as trauma,
ischemia-reperfusion or burns. They are characterized by early excessive inflammatory cytokine production and the
endogenous release of several toxic and damaging molecules. These are necessary to fight and resolve the cause of SIRS, but
often end up progressively damaging cells and tissues, leading to life-threatening multiple organ dysfunction syndrome (MODS).
As inflammasome-dependent cytokines such as interleukin-1b are critically involved in the development of MODS and death in
SIRS, and ATP is an essential activator of inflammasomes in vitro, we decided to analyze the ability of ATP removal to prevent
excessive tissue damage and mortality in a murine LPS-induced inflammation model. Our results indeed indicate an important
pro-inflammatory role for extracellular ATP. However, the effect of ATP is not restricted to inflammasome activation at all.
Removing extracellular ATP with systemic apyrase treatment not only prevented IL-1b accumulation but also the production of
inflammasome-independent cytokines such as TNF and IL-10. In addition, ATP removal also prevented systemic evidence of
cellular disintegration, mitochondrial damage, apoptosis, intestinal barrier disruption and even mortality. Although blocking ATP
receptors with the broad-spectrum P2 purinergic receptor antagonist suramin imitated certain beneficial effects of apyrase
treatment, it could not prevent morbidity or mortality at all. We conclude that removal of systemic extracellular ATP could be a
valuable strategy to dampen systemic inflammatory damage and toxicity in SIRS.
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Systemic inflammatory response syndromes (SIRS) can be
caused by infectious (sepsis) or sterile insults (e.g., trauma,
burns, pancreatitis, hemorrhage, ischemia-reperfusion or
chemically induced injury). They are characterized by so-
called systemic cytokine storms, cell damage and death,
tissue injury, and may ultimately result in multiple organ
dysfunction syndrome (MODS) and death if not curbed in
time. Despite numerous (successful) preclinical research
investments and (unsuccessful) clinical trials, no mediator-
directed treatment is available yet and sepsis has become the
number one killer worldwide.1 Most of the trials so far focused
on targeting single (early) pro-inflammatory mediators. More
recently, it has been proposed that targeting more down-
streamdetrimental pathways ‘common’ tomost SIRS, such as
mitochondrial dysfunction and/or microcirculatory failure,
could be better therapeutic strategies.2,3 Furthermore, as
the gut has repeatedly been described as the ‘motor’ of critical
illness and MODS, maintaining or repairing its barrier function
may be key to successful SIRS treatment.4 In addition, the
bench-to-bedside problem might also be due to the fact that,
traditionally, research has approached SIRS and MODS,
which are intrinsically complex and nonlinear phenomena,
through a reductionist and linear attitude. Alternatively, we
may therefore need to focus on (nonlinear) variability indices
as biomarkers and mouse-to-men translatable indications for
patient stratification, disease progression or treatment
response.5,6
The inflammatory response following either infection or
sterile tissue injury involves several types of pattern
recognition receptors (PRR), including Toll-like receptors
(TLRs), NOD-like receptors (NLRs), RIG-I-like receptors
(RLRs) and C-type Lectin receptors (CLRs). Although
sepsis was originally believed to be caused by the presence
of bacteria in the blood, the clinical signs are frequently
presented by patients without a detectable source of
infection.7 In addition, similar and overlapping signaling
networks seem to be involved in propelling our body’s
exaggerated and mortal response against both infectious
and sterile inflammation.8 Not only various microbial
components are recognized by PRRs, but also many
endogenous danger-associated molecular patterns
(DAMPs), which are usually intracellular molecules that
have reached the extracellular space, either actively or
passively following cellular damage or death. These include
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proteins, such as heat shock proteins or the chromatin-
associated high-mobility group box 1 (HMGB1), and also
(mitochondrial) DNA and purine metabolites such as uric acid,
ATP and adenosine.9 The most common Gram-negative
constituent is lipopolysaccharide (LPS), signaling via TLR4.
When injected into mammals, including humans, LPS causes
systemic inflammation and mimics most of the septic effects
such as fever or hypothermia, tachypnea, tachycardia,
cardiovascular collapse and organ dysfunction.10,11
Autocrine and/or paracrine signaling of extracellular ATP for
the inflammatory activation of macrophages has been well
established in vitro and suggested to be important in vivo as
well. For studies of the NLRP3 inflammasome and the
subsequent production of mature IL-1b and -18, treatment of
macrophage cultures with both LPS and ATP has even
become the standard working model.12,13 During systemic
inflammation, ATPmay be released by activated platelets and
leukocytes. In addition, also parenchymal cells such as
epithelial or endothelial cells may exhibit regulated ATP
release.14 This extracellular ATP can activate both P2X and
P2Y purinergic receptors, and the P2X7 receptor was
originally thought to be specifically responsible for ATP-aided
inflammasome activation in leukocytes, both in vitro and
in vivo.15,16 However, more recently the involvement of the
ATP-P2X7 axis for LPS-induced inflammasome activation
in vivo has been questioned again.16,17 Under homeostatic
conditions, extracellular ATP is removed by conversion into
adenosine in a two-step enzymatic process involving
the ectonucleotidases CD39 (ecto-apyrase) and CD73.
However, under pathological conditions, including inflamma-
tion and hypoxia, extracellular ATP levels may increase due to
active release as well as passive leakage from damaged
or dying cells, in combination with downregulation of
ectonucleotidases.18
In this paper, we suggest an important pro-inflammatory
and toxic role for extracellular ATP, which is not restricted to
inflammasome activation. We found that removal of extra-
cellular ATP by apyrase treatment not only prevented
systemic IL-1b accumulation but also precluded the induction
of inflammasome-independent cytokines, such as TNF and
IL-10, of mitochondrial damage, cellular disintegration,
apoptotic death, intestinal injury and barrier breakdown, and
subsequent mortality, in a murine model of LPS-induced
shock. In contrast to other published studies, we chose to
antagonize extracellular ATP signaling by removing extra-
cellular ATP via apyrase treatment rather than using P2X7-
deficient mice or the currently available (broad-spectrum) P2
receptor antagonists, because recent evidence excludes a
crucial role for P2X7 in LPS-induced IL-1b production in vivo17
and even suggests an important protective role for other P2X
receptors.19 Indeed, although removal of extracellular ATP
using apyrase successfully dampened various aspects of
systemic LPS-induced inflammation, including mortality, both
in pre- or post-treatment, the inhibition of P2 purinergic
receptors with suramin could not protect and even exacer-
bated the systemic effects of LPS when given as a post-
treatment, which may be due to aspecific effects of suramin
and/or protective effects of particular P2 receptors. In
addition, our results also exclude a critical role for P2
receptors in LPS-induced IL-1b production in vivo.
In conclusion, our data suggest a key role for extracellular
ATP in triggering various aspects of systemic inflammation
and cellular and tissue damage during endotoxemia, which
may be successfully and completely antagonized by ATP
removal but not by broad-spectrum blocking of its P2
receptors.
Results
Removal of extracellular ATP with apyrase dose
dependently protects against LPS-induced hypothermia
and mortality. To evaluate the contribution of extracellular
ATP to inflammation in an in vivo setting, we used the ATP
hydrolase apyrase in LPS-induced shock. Pretreatment with
increasing doses (from 5 to 15 IU per mouse) increasingly
protected mice against a lethal challenge with LPS
(Figures 1a and b). Next, we used 15 IU apyrase to
determine the capacity of apyrase to protect as a therapeutic
post-treatment. As shown in Figures 1c and d, apyrase also
protected significantly when given 30min after the LPS
challenge. However, when given 2h after challenge, apyrase
could no longer protect (not shown).
Extracellular ATP is necessary for systemic cytokine
storm induction and inflammation. Using both genetic
and therapeutic approaches, we recently determined the
critical involvement of both endogenous IL-1b and IL-18 in
several models of inflammatory and septic shock.20 To
induce IL-1b/IL-18 maturation and release, the NLRP3
inflammasome is essential, and LPS-induced activation of
the inflammasome has been suggested to result from particle
internalization and/or ATP signaling.21 Hence, we decided to
analyze the effect of apyrase on LPS-induced cytokine
induction. As anticipated based on our hypothesis, IL-1
bioactivity and IL-1b protein levels in serum were significantly
reduced (Figures 2a and b). Surprisingly, however, we found
that also endogenous TNF and IL-10 production were
markedly inhibited by apyrase treatment (Figures 2c–e),
whereas IL-6 levels were not affected significantly
(Figure 2f). Also the production of IL-12 (produced from 2h
on) and IFN-g (undetectable at 2 h, but systemically present
at 6 h), pro-inflammatory cytokines that may link innate with
adaptive immunity, was reduced thanks to apyrase treat-
ment, albeit not significantly (not shown). The reduced
systemic TNF and IL-1 production was reflected in reduced
leukocyte infiltration into liver tissue (Figure 3a).
Apyrase treatment reduces cellular disintegration,
mitochondrial dysfunction and intestinal barrier
breakdown. Intracellular proteins such as hexosaminidase,
a lysosomal enzyme, are indicative for cellular damage and
(necrotic) disintegration when detected systemically. As
illustrated in Figure 3b, hexosaminidase release into the
circulation was significantly attenuated by apyrase. Similarly,
tissue breakdown demonstrated by increased lactate dehy-
drogenase (LDH) serum levels 6 h after LPS was dampened
by apyrase treatment (not shown). In addition, apyrase also
protected mitochondrial complex I and II activity in the liver
(Figures 3c and d). In the small intestine, apyrase completely
prevented apoptotic death of epithelial cells, as evidenced by
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Figure 1 Apyrase dose dependently protects against LPS-induced shock. (a, b) Mice were injected i.v. with 175mg (8 mg/kg) Sigma LPS, and pre-treated i.p. with 5, 10 or
15 U apyrase 30min before. ****Po0.0001, ***Po0.001, compared with LPS controls, n¼ 6. (c, d) Mice were injected i.v. with 175mg Sigma LPS, and treated i.p. with 15 U
apyrase 30min before or after LPS challenge. ****Po0.0001, ***Po0.001, compared with LPS controls, n¼ 6
Figure 2 Apyrase inhibits systemic TNF, IL-1 and IL-10, but not IL-6 production. (a, c) Systemic IL-1 and TNF induction determined by bioassay (n¼ 4). **Po0.01,
***Po0.001, compared with LPS alone. (b, d, e) Serum IL-1b, TNF and IL-10 levels 2 h after LPS challenge, determined by Bio-Plex (n¼ 3). (f) IL-6 concentrations in serum,
assayed via Bio-Plex. *Po0.05, ***Po0.001, ****Po0.0001, compared with LPS alone
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TUNEL staining (Figure 3e), as well as the early disappear-
ance of mucin-producing goblet cells (Figure 3f).
Removal of extracellular ATP is superior over blocking
ATP receptors for protection. ATP is sensed by both P2X
and P2Y purinergic receptors, which may be blocked by the
broad-spectrum antagonist suramin. When given as a pre-
treatment, suramin efficiently prevented LPS-induced TNF
production, leukocyte infiltration and necrotic tissue damage
(Figures 4a–c). Nevertheless, suramin could not prevent
IL-1b production (Figure 4d) or protect against mortality
(Figure 4e). Surprisingly, when given as a post-treatment,
suramin even accelerated mortality (Figure 4e), which was
accompanied by increased levels of circulating TNF and
IL-1b, as well as evidence of early tissue damage and
exacerbated neutrophil infiltration (Figures 4d and f–h).
Discussion
Our results show that extracellular ATP is an important
mediator of inflammation-associated systemic damage and
toxicity in vivo. To study the possible involvement of ATP
release, we used a model of LPS-induced systemic
inflammation in mice. Removing extracellular ATP by means
of the ATPase apyrase significantly protected against
mortality, even when given as a post-treatment. This
protection correlated with markedly reduced production of
both the pro-inflammatory and cell death inducing cytokines
TNF and IL-1, and the anti-inflammatory cytokine IL-10.
Although apyrase protected as a post-treatment when given
30min after LPS, there was no protective effect when given
2h after challenge. This is not surprising, as both TNF and
IL-1 are ‘early’ pro-inflammatory and toxicity-inducing
cytokines, markedly increasing (and in case of TNF even
peaking) within the first 2 h after LPS.17 Extracellular ATP had
already been suggested to be an essential trigger for
activation of the IL-1b producing caspase-1 in the multiprotein
inflammasome complex in macrophages,21 but our current
results clearly show that in an in vivo setting ATP signaling is
involved in the production of other cytokines as well.
We have recently documented the critical involvement of
RIPK-dependent necroptosis (also coined ‘regulated necro-
sis’, to distinguish it from accidental necrosis) in the release of
endogenous DAMPs and subsequent mortality induced by
either TNF or murine septic shock,22 as well as the crucial
involvement of both IL-1b and IL-18 in several models of
Figure 3 Apyrase prevents inflammation and tissue damage. (a) CD45 staining quantification in liver sections 6 h after LPS challenge, n¼ 3–7. (b) Hexosaminidase in
serum indicates cellular disintegration. Plotted is the relative increase compared with PBS-treated animals, n¼ 7. (c, d) Mitochondrial complex I and II activity in liver tissue 6 h
after LPS injection, n¼ 3–4. (e) TUNEL staining of apoptotic cell death in the jejunum, n¼ 4-6. (f) AB/PAS staining was used to visualize mucin-positive goblet cells in the
jejunum, n¼ 6–9. *Po0.05, **Po0.01, ***Po0.001, ****Po0.0001, compared with LPS (a, b) or PBS controls (c–f), or as indicated by horizontal lines
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inflammatory and septic shock.20 In our current study,
apyrase successfully prevented systemic evidence of LPS-
induced necrotic and mitochondrial damage as well, most
probably thanks to its remarkable effect on both endogenous
TNF and IL-1. In addition, preventing caspase-1 activation
may also contribute to reducing inflammatory cell death.23
For decades already, the gut has been proposed as the
‘motor’ of several critical illnesses, driving MODS and
mortality.4 The intestinal barrier, necessary to protect against
microbiota and their toxins, consists of both a physical and an
immunological part. The physical section is composed of a
tightly sealed epithelial lining, reinforced by a thick mucus
layer produced by goblet cells. Early after a systemic
inflammatory insult, enterocytes undergo apoptosis, and
mucin-positive goblet cell loss is observed. Treatment with
apyrase completely prevented enterocyte apoptosis, which
has been shown to be an important cause of increased
permeability. This ismost probably a reflection of the inhibitory
effect of apyrase on systemic TNF production,24,25 possibly
aided by its negative effect on IL-1b production.26 In addition,
if mice were treated with apyrase, mucin-positive goblet cells
started disappearing only at later time points. The exact
mechanism of mucin- and/or goblet cell loss has not been
elucidated yet, but it is generally believed that the formation of
a thick mucus layer contributes significantly to intestinal
barrier protection, providing a sterile zone and thusminimizing
commensal bacterial contact with epithelial cells.27,28 All
things considered, our data indicate that extracellular ATP
removal may have a beneficial effect on intestinal barrier
maintenance during inflammation, and consequently on the
Figure 4 Suramin reduces inflammation and necrotic damage, but offers no survival benefit. (a–c) Suramin pre-treatment at  30min reduces systemic TNF (2 h), CD45
staining in the liver (6 h) and systemic hexosaminidase activity (6 h), n¼ 3. (d) Suramin does not reduce systemic IL-1b levels when given 30min before or after LPS, rather
contrary (2 h), n¼ 3. (e) In contrast to apyrase, suramin does not prevent LPS-induced mortality. When given as a post-treatment (þ 30min), suramin even accelerates
mortality (e), correlated with increased TNF production (f, 2 h), earlier evidence of cellular damage (g, 2 h) and enhanced myeloperoxidase (MPO) accumulation in the liver
(h, 6 h). *Po0.05, **Po0.01, ****Po0.0001, compared with PBS controls (except for e), with LPS (only for e), or as indicated by horizontal lines
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development and progression of SIRS and life-threatening
MODS.
Remarkably, while apyrase protected as both pre- or post-
treatment, the broad-spectrum P2 receptor antagonist
suramin could not protect at all, despite inhibitory effects on
TNF production, systemic evidence of cellular disintegration
and inflammation, when given as a pre-treatment. However, in
contrast to apyrase, suramin could not reduce systemic IL-1b
levels, and, when injected as a post-treatment, suramin
actually aggravated and/or accelerated TNF and IL-1b
production, (necrotic) cellular damage and mortality. These
results indicate that removing extracellular ATP is more
successful than blocking P2 receptors to prevent systemic
production/release of IL-1b in vivo. Despite numerous reports
on the role of P2X7 receptors in ATP-mediated inflammasome
activation and mature IL-1b production in macrophages
in vitro, its role in vivo has recently been questioned.17
Corroborating this, our results not only question the significant
involvement of P2X7 receptors in particular, but actually of P2
receptors in general, in the LPS-induced release of systemic
IL-1b. In addition, our data may also suggest either that ATP
contributes critically to toxicity in a P2-independent manner or,
and probably more likely, that certain P2 receptors may
mediate beneficial effects during systemic inflammation.
Many inflammatory mediators or pathways are known to
possess two-sided Janus faces. Only recently, P2X1-deficient
mice were shown to suffer more from LPS-induced morbidity
due to exaggerated hemostatic disturbances and neutrophil
accumulation.19 When given as a post-treatment, we found
that suramin indeed augmented MPO infiltration, toxicity and
morbidity. The reason why apyrase treatment does not affect
the potentially protective P2 signaling pathway(s) may
suggest that agonists other than ATP are involved in these
protective effects.29 Alternatively, suramin may have detri-
mental side effects unrelated to ATP signaling, for instance by
activating sarcoplasmic reticulum calcium release via the
stimulation of ryanodine receptors30 or by its positive effect on
tyrosine phosphorylation-dependent signaling.31
Taken together, our data suggest that systemic removal of
extracellular ATP could be a better strategy than preventing
ATP from signaling through its P2 purinergic receptors to
dampen systemic inflammatory cell and tissue damage and
toxicity. Removing extracellular ATP with apyrase very
efficiently prevented the production of the highly inflammatory
and destructive cytokines TNF and IL-1, which correlated with
reduced leukocyte infiltration, mitochondrial and tissue
damage, and destruction of the vital gut barrier. As both pro-
inflammatory cytokines and leukocyte extravasation are
strictly essential to kill and eliminate microbes, ATP removal
should only be considered in case of sterile inflammation or in
combination with broad-spectrum antibiotics.
Materials and Methods
Laboratory animals. Female C57BL/6J mice were purchased from Janvier
(Le Genest St Isle, France) and housed in temperature-controlled, air-conditioned SPF
facilities with 14/10 h light/dark cycles, food and water ad libitum. They were used at
10–16 wk. All experiments were approved by, and performed according to the
guidelines of the animal ethics committee from Ghent University, Belgium, and the
investigation conforms to the Directive 2010/63/EU of the European Parliament. For
each experiment, mice were monitored several times daily for 5 d. Moribund or surviving
animals were euthanized by CO2 asphyxiation followed by cervical dislocation.
Reagents, injections and body temperature measurements.
E. coli LPS (serotype 0111:B4), apyrase (grade VII from potato) and suramin
sodium salt were purchased from Sigma (St. Louis, MO, USA) and injected in
LPS-free PBS, intravenously for LPS, intraperitoneally for apyrase or suramin.
Rectal body temperature was recorded with an electronic thermometer (model
2001; Comark Electronics, Littlehampton, UK).
Blood collection, NOx
 and cytokine measurements. Blood was
collected from the tail vein or via cardiac puncture. Determination of NO2
 þNO3
(NOx
 ) was done as described.32 For determination of TNF and IL-1 activity in
serum, bioassays were performed.33 To corroborate the bioassay results, and to
determine IL-6 and IL-10, Bio-Plex cytokine assay kits (Bio-Rad, Hercules, CA,
USA) were used.
Determination of cellular and mitochondrial damage, and
leukocyte infiltration. Hexosaminidase34 and lactate dehydrogenase
(Cytotox96, Promega, Madison, WI, USA) activities were determined in serum.
Whole-liver tissue, snap frozen in liquid nitrogen, was used for the measurement of
mitochondrial complexes; for complex I, the rotenone sensitive rate of NADH
oxidation was spectrophotometrically monitored at 340 nm in permeabilized tissue,
whereas complex II activity was determined by measuring the reduction of
dichloroindophenol at 600 nm, coupled to the oxidation of CoQ2 using succinate as
a substrate, and TTFA to determine specificity for complex II activity.
Histopathology was evaluated on paraffin sections. In the jejunum, apoptosis
was identified by the terminal deoxynucleotidyl-transferase-mediated deoxyuridine
triphosphate nick-end labeling (TUNEL) technique using the ApopTag Peroxidase
In Situ Apoptosis Detection kit (Millipore, Billerica, MA, USA); goblet cells were
visualized using AB/PAS (Alcian blue combined with Periodic acid-Schiff) staining.
To stain for leukocytes or neutrophils in liver sections, CD45 (30-F11, BD
Pharmingen, Erembodegem, Belgium) or MPO (A-0398, Dako, Glostrup,
Denmark) immunohistochemistry were performed.
Statistics. Statistics were performed using GraphPad Prism. Significant
differences in systemic cytokines and NOx
 were examined using a one-way
ANOVA with Bonferroni (for comparison of all pairs) or Dunnett (for comparison
with a control group) post test. Data shown are always means±S.E.M. Two-way
ANOVA was used to compare temperature or hexosaminidase curves (repeated
measures), with Sidak’s post hoc test for multiple comparisons. Survival curves
were compared via a logrank test.
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